TSW
VIR icon

Thompson Siegel & Walmsley’s Vir Biotechnology VIR Stock Holding History

Thompson Siegel & Walmsley’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$824K Buy
+92,000
New +$733K 0.01% 328

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Thompson Siegel & Walmsley's VIR Position: Q1 2026 in Review

Thompson Siegel & Walmsley opened a new position in Vir Biotechnology (VIR) in Q1 2026: 92,000 shares worth $824K. The stake represents 0.01% of the portfolio and ranks #328 among its holdings.

251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Thompson Siegel & Walmsley held 92,000 shares of Vir Biotechnology worth $824K as of Q1 2026.
  • Vir Biotechnology was a new Thompson Siegel & Walmsley position in Q1 2026.
  • Vir Biotechnology made up 0.01% of Thompson Siegel & Walmsley's portfolio in Q1 2026, its #328 holding.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2026, filed 11 May 2026.